A detailed history of Pvg Asset Management Corp transactions in Bio Atla, Inc. stock. As of the latest transaction made, Pvg Asset Management Corp holds 36,000 shares of BCAB stock, worth $14,760. This represents 0.12% of its overall portfolio holdings.

Number of Shares
36,000
Holding current value
$14,760
% of portfolio
0.12%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 21, 2025

BUY
$0.59 - $2.37 $21,240 - $85,320
36,000 New
36,000 $21,000
Q4 2023

Mar 12, 2024

BUY
$1.27 - $3.18 $82,975 - $207,765
65,335 New
65,335 $160,000

Others Institutions Holding BCAB

About BioAtla, Inc.


  • Ticker BCAB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 36,304,100
  • Market Cap $14.9M
  • Description
  • BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ...
More about BCAB
Track This Portfolio

Track Pvg Asset Management Corp Portfolio

Follow Pvg Asset Management Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pvg Asset Management Corp, based on Form 13F filings with the SEC.

News

Stay updated on Pvg Asset Management Corp with notifications on news.